作者：
Takahiro,Ishii [1]
;
Takuya,Kobayakawa [1]
;
Kouki,Matsuda [2]
;
Kiyomi,Nigorikawa [3]
;
Peter,Bolah [1]
;
Airi,Noborio [2]
;
Kohei,Tsuji [1]
;
Nami,Ohashi [4]
;
Kazuhisa,Yoshimura [5]
;
Wataru,Nomura [3]
;
Hiroaki,Mitsuya [6]
;
Kenji,Maeda [7]
;
Hirokazu,Tamamura [8]
作者单位：
Department of Medicinal Chemistry, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU), Chiyoda-ku, Tokyo 101-0062, Japan.
[1]
Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Kagoshima 890-8544, Japan.
[2]
Department of Genome and Biomolecular Engineering for Drug Discovery, School of Pharmaceutical Sciences and Graduate School of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima 734-8553, Japan.
[3]
Laboratory of Drug Design and Medicinal Chemistry, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan.
[4]
Institute of Public Health, Bureau of Social Welfare and Public Health, Tokyo Metropolitan Government, Shinjuku-ku, Tokyo 169-0073, Japan.
[5]
Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Shinjuku-ku, Tokyo 162-8655, Japan.
[6]
Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States.
[7]
Department of Clinical Sciences, Kumamoto University Hospital, Chuo-ku, Kumamoto 860-8556, Japan.
[8]
DOI
10.1021/acsinfecdis.4c00194
PMID
38771724
发布时间
2024-06-14
换一批
换一批
